Compare with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs JUBILANT PHARMOVA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES JUBILANT PHARMOVA ALKEM LABORATORIES/
JUBILANT PHARMOVA
 
P/E (TTM) x 22.4 13.5 166.1% View Chart
P/BV x 5.4 2.5 214.6% View Chart
Dividend Yield % 0.9 0.6 151.7%  

Financials

 ALKEM LABORATORIES   JUBILANT PHARMOVA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
JUBILANT PHARMOVA
Mar-19
ALKEM LABORATORIES/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs2,720898 302.9%   
Low Rs1,660618 268.9%   
Sales per share (Unadj.) Rs697.9572.0 122.0%  
Earnings per share (Unadj.) Rs96.136.2 265.3%  
Cash flow per share (Unadj.) Rs117.359.5 197.0%  
Dividends per share (Unadj.) Rs25.004.50 555.6%  
Dividend yield (eoy) %1.10.6 192.2%  
Book value per share (Unadj.) Rs515.2301.9 170.7%  
Shares outstanding (eoy) m119.57159.28 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.3 236.9%   
Avg P/E ratio x22.820.9 108.9%  
P/CF ratio (eoy) x18.712.7 146.7%  
Price / Book Value ratio x4.32.5 169.4%  
Dividend payout %26.012.4 209.4%   
Avg Mkt Cap Rs m261,879120,694 217.0%   
No. of employees `00014.32.4 599.6%   
Total wages/salary Rs m15,05519,260 78.2%   
Avg. sales/employee Rs Th5,822.638,120.6 15.3%   
Avg. wages/employee Rs Th1,050.58,058.4 13.0%   
Avg. net profit/employee Rs Th802.02,414.3 33.2%   
INCOME DATA
Net Sales Rs m83,44491,108 91.6%  
Other income Rs m1,042357 291.6%   
Total revenues Rs m84,48691,466 92.4%   
Gross profit Rs m14,73417,390 84.7%  
Depreciation Rs m2,5283,709 68.1%   
Interest Rs m6512,198 29.6%   
Profit before tax Rs m12,59811,840 106.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,1053,268 33.8%   
Profit after tax Rs m11,4935,770 199.2%  
Gross profit margin %17.719.1 92.5%  
Effective tax rate %8.827.6 31.8%   
Net profit margin %13.86.3 217.5%  
BALANCE SHEET DATA
Current assets Rs m54,96045,848 119.9%   
Current liabilities Rs m32,43320,897 155.2%   
Net working cap to sales %27.027.4 98.6%  
Current ratio x1.72.2 77.2%  
Inventory Days Days8057 140.1%  
Debtors Days Days7251 141.6%  
Net fixed assets Rs m32,71065,498 49.9%   
Share capital Rs m239159 150.1%   
"Free" reserves Rs m61,36847,930 128.0%   
Net worth Rs m61,60748,089 128.1%   
Long term debt Rs m1,59242,429 3.8%   
Total assets Rs m99,433114,685 86.7%  
Interest coverage x20.46.4 318.8%   
Debt to equity ratio x00.9 2.9%  
Sales to assets ratio x0.80.8 105.6%   
Return on assets %12.26.9 175.8%  
Return on equity %18.712.0 155.5%  
Return on capital %21.012.4 168.9%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06112,422 129.3%   
Fx outflow Rs m2,48317,227 14.4%   
Net fx Rs m13,578-4,805 -282.6%   
CASH FLOW
From Operations Rs m5,85111,215 52.2%  
From Investments Rs m-7,414-10,118 73.3%  
From Financial Activity Rs m7926,574 12.0%  
Net Cashflow Rs m-7317,612 -9.6%  

Share Holding

Indian Promoters % 66.9 45.6 146.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 33.1 8.7 380.5%  
FIIs % 0.0 21.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.1 -  
Shareholders   68,381 23,815 287.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  ELDER PHARMA  ALEMBIC  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS